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INTRODUCTION 
 
                          India is one of the largest and most populated countries in 
the world, with over  one  billion inhabitants. Of this number, it's estimated 
that around 2.4 million people are currently living with HIV. 
                          In  recent  decades, the  dramatic  spread  of  the  HIV 
epidemic   in sub-Saharan Africa   has   resulted  in  notification  rates  of  
TB  increasing  up  to 10 times   in  some countries.  The  incidence  of  TB  
is  also  increasing  in  other high  HIV  prevalence  countries, where  the  
population  with  HIV  infection  and TB  overlap. Even  those  countries  
with  well  organized  national  tuberculosis programs   have  seen  an  
increase  in  TB cases. This  is  the  underlying  factor that   suggests  that  
TB  control  will  not  make  much  head  way  in  HIV prevalent  settings  
unless  HIV control  is  also  achieved. TB  is  the  most common  treatable  
HIV-related   disease   and  a   leading   killer  of  people  living   with   
HIV/AIDS (PLWHA).  
                          The   World  Health  Organisation (WHO)  cites  TB  
treatment  as one   of   the  most  cost-effective  health  interventions   
available – at  a  cost  of only  $10  for  every  year  of  life  gained. 
 BACKGROUND  OF  THE  STUDY 
                 As    HIV  progressively destroys  the  immune  system, there is  
a greater chance of a child infected with HIV developing  tuberculosis. The 
development of   active TB  accelerates  the  progression of  HIV  disease  
towards full-blown  AIDS, because  the  replication  rate of the HIV virus 
is increased during  the  active  phase  of  TB. 
               TB  is  curable, even  in  a   children  who  is  HIV positive. 
Curing  an HIV  positive  children of  TB  not  only  improves  their  
quality of  life, and  gives   them  several  more years  of  life, it  also  
reduces  transmission  to others in  the  community. TB  is  the  most  
common  treatable  HIV-related disease   and a  leading  killer  of   
children  living  with  HIV/AIDS. 
            So my  study  is  aimed  to  screen  for  TB  coinfection  in HIV  
positive  children, registered  and  followed  up  at  ART centre, Madurai . 
This  will  help  in  early  initiation  of  treatment  and  improve  the  
outcome. 
 
 
REVIEW  OF  LITERATURE 
HISTORY  OF  TB
(1) 
                   Mycobacterium  tuberculosis, the  bacteria  that  causes 
 tuberculosis, has been around for centuries. Recently, fragments of the 
spinal columns from Egyptian  mummies  from  2400 B.C.E. were  found  
to  have definite  signs  of  the  ravages  of  this  terrible  disease. Also 
called consumption,  TB  was identified as the most widespread disease in 
ancient Greece, where it was almost always fatal. But it wasn't until 
centuries later that the first descriptions of the disease began to appear. 
Starting in the late seventeenth century, physicians began to identify 
changes in the lungs common in all consumptive, or  TB, patients. At  the 
same time, the earliest references to the fact that the disease was infectious 
began to appear. 
                       In 1720, the English doctor Benjamin Marten was the first to 
state that  TB could be caused by ―wonderfully minute living creatures.‖ 
He went further to say that it was likely that ongoing contact with a 
consumptive patient could  cause a healthy person to get sick. Although  
Marten's  findings didn't help to cure TB, they did  help  people to better 
understand the disease.  
                       The  sanitorium, which was introduced in the mid-nineteenth 
century, was the first positive step to contain TB. Hermann Brehmer, a 
Silesian botany student who had TB, was told by his doctor to find a 
healthy climate. He moved to the Himalayas and continued his studies. He 
survived his bout with the illness, and after he received his doctorate, built 
an institution in Gorbersdorf, where TB patients could come to recuperate. 
They received good nutrition and were outside in fresh air most of the day. 
This became the model for the development of sanitoria  around  the  
world. Tuberculosis  is  spread  through  the  air, so  everyone  is  at  some  
risk. 
                     In  1865, French  military  doctor Jean-Antoine Villemin 
demonstrated that TB could be passed from people to cattle and from cattle 
to rabbits. In  1882, Robert  Koch discovered  a staining technique that 
allowed him to see the bacteria that cause TB under a microscope. 
CAUSATIVE  ORGANISM 
             Tuberculosis  is an infection caused by the rod-shaped, non–spore-
forming, aerobic bacterium  Mycobacterium tuberculosis. Mycobacteria 
typically measure 0.5 μm by 3 μm, are classified as acid-fast bacilli, and 
have a unique cell wall structure crucial to their survival. The well-
developed cell wall contains  a considerable amount of a fatty acid, 
mycolic acid, covalently attached to  the underlying  peptidoglycan-bound  
polysaccharide arabinogalactan, providing  an  extraordinary lipid barrier. 
This  barrier  is  responsible for many of the  medically  challenging  
physiological  characteristics  of  tuberculosis, zincluding  resistance  to 
antibiotics  and host defense mechanisms. The composition and quantity of 
the cell wall components affect the bacteria‘s virulence and growth rate. 
The  peptidoglycan  polymer  confers  cell wall  rigidity and is just external 
to the bacterial cell membrane, another contributor to the permeability 
barrier of mycobacteria. Another important component of the cell wall  is  
lipoarabinomannan,  a  carbohydrate structural antigen on the outside of 
the organism that is immunogenic and facilitates the survival of 
mycobacteria within  macrophages.
(2)
 The cell wall is key to the survival of 
mycobacteria, and  a more  complete  understanding of  the biosynthetic 
pathways and gene functions and  the development of  antibiotics  to 
prevent  formation of the cell wall are areas of great interest.(3)  
TRANSMISSION 
                      Mycobacterium tuberculosis  is spread by small airborne 
droplets, called  droplet  nuclei, generated  by the coughing, sneezing, 
talking, or singing  of a  person  with  pulmonary  or laryngeal 
tuberculosis. These  minuscule  droplets can remain airborne for minutes to 
hours after expectoration.(2) The number of bacilli  in  the  droplets, the  
virulence  of  the  bacilli, exposure  of  the  bacilli to UV light, degree of 
ventilation, and occasions for aerosolization all influence transmission. 
Introduction  of  M tuberculosis  into  the  lungs  leads  to infection of  the  
respiratory system; however, the organisms can spread to other organs, 
such as the lymphatics, pleura, bones/joints, or meninges, and cause 
extrapulmonary  tuberculosis. 
PATHOPHYSIOLOGY 
                    Once  inhaled, the  infectious  droplets  settle  throughout the  
airways. The  majority  of  the  bacilli  are  trapped  in  the  upper parts of 
the airways where the mucus-secreting goblet cells exist. The mucus 
produced catches foreign substances, and the cilia on the surface of the 
cells constantly beat the mucus and its  entrapped  particles  upward  for  
removal. This  system provides the body with  an  initial  physical  defense  
that  prevents  infection in most persons exposed  to  tuberculosis. 
                         Bacteria  in droplets  that  bypass  the  mucociliary  system  
and  reach  the alveoli are quickly surrounded and engulfed by alveolar 
macrophages, the most abundant immune effector cells present in alveolar 
spaces. These  macrophages, the  next  line  of  host defense, are part of the 
innate immune system and provide an opportunity for the body to destroy 
the invading  mycobacteria  and  prevent infection.
11
 Macrophages are 
readily available  phagocytic  cells that combat many pathogens without 
requiring previous exposure to the pathogens. Several mechanisms and 
macrophage receptors are involved in uptake of the mycobacteria.The 
mycobacterial lipoarabinomannan  is  a  key  ligand for a macrophage 
receptor.
(4)
The complement system also plays a role in the phagocytosis of  
the bacteria. The complement protein C3 binds to the cell wall and 
enhances recognition of the mycobacteria  by  macrophages. Opsonization 
by C3 is rapid, even in the air spaces of a host with no previous exposure 
to M tuberculosis.
(5)
 The subsequent phagocytosis by macrophages initiates 
a cascade of events that results in either successful  control  of  the  
infection, followed by latent tuberculosis, or progression to active disease, 
called primary progressive tuberculosis. The outcome is essentially 
determined by the quality of the host defenses and the balance  that  occurs  
between  host  defenses  and  the  invading  mycobacteria.  
After being ingested by macrophages, the mycobacteria continue to 
multiply slowly, with bacterial cell division occurring  every 25 to 32 
hours. Regardless of  whether  the  infection  becomes controlled  or  
progresses, initial development involves  production  of  proteolytic  
enzymes  and  cytokines  by  macrophages in an  attempt  to degrade  the  
bacteria. Released  cytokines  attract T lymphocytes to the site, the cells 
that constitute cell-mediated immunity. Macrophages then present 
mycobacterial antigens on their surface to the T cells.(6) This initial 
immune process continues for 2 to 12 weeks; the microorganisms  continue  
to grow until they reach sufficient numbers to fully elicit  the  cell-
mediated immune response, which can be detected by a skin test.  
For persons with intact cell-mediated immunity, the next defensive step is 
formation  of  granulomas  around  the  M tuberculosis organisms.  These 
nodular – type lesions form from an accumulation of activated 
T lymphocytes and macrophages, which creates a micro-
environment that limits replication and the spread of the 
mycobacteria. This environment destroys macrophages  and produces early 
solid necrosis at the center of the lesion; however, the  bacilli are able to 
adapt to survive.(7) In fact, M tuberculosis organisms can change their 
phenotypic expression, such as protein regulation, to enhance survival. By 
2 or 3 weeks, the necrotic environment resembles soft cheese, often 
referred to caseous necrosis, and is characterized by low oxygen levels, 
low pH, and limited nutrients. This condition restricts further growth and 
establishes  latency. Lesions in persons with an adequate immune system 
generally undergo  fibrosis  and calcification, successfully controlling the 
infection so that the  bacilli  are  contained  in  the dormant, healed 
lesions.(7) Lesions  in  persons with less  effective  immune  systems 
progress to primary progressive tuberculosis.  
PATHOPHYSIOLOGY   IN   IMMUNOCOMPROMISED 
                         For less immunocompetent persons, granuloma formation 
is initiated  yet  ultimately is unsuccessful in containing the bacilli. The 
necrotic tissue  undergoes  liquefaction,  and  the  fibrous  wall loses 
structural integrity. The  semiliquid  necrotic  material  can  then  drain into 
a bronchus or nearby blood vessel, leaving an air-filled cavity at the 
original site. In patients infected with  M tuberculosis,  droplets can be 
coughed up from the bronchus and infect other persons. If discharge into a 
vessel occurs, occurrence of extrapulmonary  tuberculosis  is  likely. 
Bacilli can also drain into the lymphatic system  and collect in  the 
tracheobronchial  lymph nodes of the affected lung, where the organisms 
can  form  new caseous granulomas.(7)  
CLINICAL  MANIFESTATIONS 
                            As the cellular processes occur, tuberculosis may develop 
differently  in  each patient, according to the status  of the patient‘s 
immune system. Stages  include latency, primary disease, primary 
progressive disease, and extrapulmonary disease. Each stage has different 
clinical manifestations.  
 
 LATENT  TUBERCULOSIS 
                           Mycobacterium  tuberculosis  organisms  can be enclosed, 
as previously  described, but  are  difficult  to completely  
eliminate. Persons  with latent tuberculosis have no signs or symptoms of 
the disease, do not feel sick, and are  not  infectious. However, viable  
bacilli  can persist in the  necrotic material for years or even a lifetime, and 
if the immune system later becomes compromised, as it does in many 
critically ill patients, the disease can be reactivated. Although  coinfection  
with human immunodeficiency virus is the most  notable  cause  for 
progression to active disease, other factors, such as  sepsis, renal failure, 
malnutrition  also  contribute. 
PRIMARY  DISEASE 
                            Primary pulmonary tuberculosis is often asymptomatic, 
so that the results of diagnostic tests  are the only evidence of the disease. 
Although primary disease essentially exists subclinically, some self-
limiting findings might be noticed in an assessment. Associated 
paratracheal lymphadenopathy  may  occur because the bacilli spread from 
the lungs through the lymphatic system. If the primary lesion enlarges, 
pleural effusion is a distinguishing finding. This effusion develops because 
the bacilli infiltrate the pleural space from an adjacent area. The effusion 
may remain small and resolve spontaneously, or it may become large 
enough to induce symptoms such as fever, pleuritic chest pain, and 
dyspnea.  
PRIMARY  PROGRESSIVE  TUBERCULOSIS 
                   Active  tuberculosis  develops  in only 5% to 10% of persons 
exposed to  M tuberculosis. When  a  patient  progresses to active 
tuberculosis, early signs and  symptoms  are often nonspecific. 
Manifestations  often  include  progressive fatigue, malaise, weight loss, 
and a low-grade  fever  accompanied  by chills  and night  
sweats.(8) Wasting, a classic feature of tuberculosis, is  due to the lack of 
appetite and the altered metabolism associated with the inflammatory and 
immune responses. Wasting involves the loss of both fat and lean tissue; 
the decreased muscle mass contributes to the fatigue.(9) Finger clubbing, a 
late sign of poor oxygenation, may occur; however, it does not indicate the 
extent of disease.(10) A cough eventually develops in most patients. 
Although the cough may initially be non productive, it  advances  to a 
productive cough of purulent sputum. The sputum  may also be streaked  
with  blood. Hemoptysis  can be due to destruction of  a  patent vessel 
located  in  the wall of the cavity, the rupture of a dilated vessel in a cavity, 
or the formation of an aspergilloma in an old cavity. The inflamed 
parenchyma  may cause pleuritic chest pain. Extensive disease may lead to 
dyspnea  or  orthopnea  because the increased interstitial volume leads to a 
decrease in lung diffusion capacity. Although many patients with active 
disease have few physical findings, rales may be detected over involved 
areas during inspiration, particularly after a cough. Hematologic studies 
might reveal anemia, which is the cause of the weakness and fatigue. 
Leukocytosis may also occur because of the large increase in the number 
of leukocytes, or white blood cells, in response to the infection.  
EXTRA- PULMONARY  TUBERCULOSIS 
                 Although the pulmonary system is the most common location 
for tuberculosis, extrapulmonary disease occurs in more than 20% of 
immunocompetent  patients, and  the risk for extrapulmonary disease 
increases with  immunosuppression.
(11)
The most serious location is the 
central nervous system, where  infection may result in meningitis or space-
occupying tuberculomas. If not treated, tubercular meningitis is fatal in 
most cases, making rapid detection of the mycobacteria 
essential. Headaches and change in mental status  after  possible  exposure 
to tuberculosis or in high risk groups should prompt  consideration  of this 
disease as a differential diagnosis. Another fatal form of extrapulmonary 
tuberculosis is infection of the bloodstream by mycobacteria; this form of 
the disease is called disseminated or miliary tuberculosis. The bacilli can 
then spread throughout the body, leading to multiorgan 
involvement. Miliary tuberculosis progresses rapidly and can be difficult to 
diagnose because of its systemic and nonspecific signs and symptoms, 
such as fever, weight loss, and weakness.
 
Lymphatic tuberculosis is the 
most common  extrapulmonary  tuberculosis, and cervical adenopathy 
occurs most often. Other possible locations include bones, joints, pleura, 
and genitourinary system 
 DEFINITIONS FOR CATEGORIZING FOR TREATMENT OF  
                        PEDIATRIC TUBERCULOSIS 
                   IAP  along  with  along  with  working  group  on  tuberculosis  
has  given  the  following  definitions  for childhood  tuberculosis
(12) 
A. Case definitions for site 
Pulmonary: Refers to disease involving lung parenchyma. 
 Extra Pulmonary: Refers to disease involving sites other than lung  
parenchyma Both pulmonary  and  Extra pulmonary constitutes 
Pulmonary. 
 Extra- Pulmonary involving several sites is defined by most severe site. 
B. Case definitions for severity 
Less severe Pulmonary TB 
          • Primary Pulmonary complex (PPC) 
Severe Pulmonary TB                                      
           All other except PPC e.g.                      
                 Progressive primary disease 
                 Fibro-cavitatory disease 
                 Miliary 
Extra-Pulmonary TB 
Less severe extra-pulmonary TB 
    Single Lymph node site 
    Unilateral pleural effusion 
Severe Extra-Pulmonary TB  
   Meningitis Spinal or Bone or Peripheral joints  
   Bilateral or extensive pleural effusion  
   Intestinal 
   Genitourinary 
   Peritonitis 
   Pericarditis 
   Adrenal glands 
 
C. Case definition for bacteriology 
Smear positive- Sputum / Gastric aspirate /BAL/any other tissue or 
fluid 
Any sample positive for acid fast bacilli on staining 
Smear Negative- None positive 
 
D. Type of patient as per history of previous ATT 
New Case  A  patient who has had no previous ATT or had it for less than 
4 weeks. 
Relapse: Patient declared cured/completed therapy in past and has 
evidence of recurrence. 
Treatment Failure: Patient who fails to respond/deteriorates after 12 weeks 
of compliant intensive phase. 
Treatment  after  default: A patient who has taken treatment for at least 4 
weeks and comes after interruption of treatment for 2 months and has 
active disease. 
DIAGNOSIS of TB  in CHILDREN 
                 The diagnosis of tuberculosis in childhood  continues to be 
surrounded by considerable  uncertainty. Although an elevated erythrocyte 
sedimentation  rate (ESR) may be expected in children with  tuberculosis, a 
recent study found that one-third of   children with TB had a normal ESR 
at the time of  diagnosis, suggesting little value in using ESR as a  
diagnostic test for childhood tuberculosis. The  following  investigations  
were  routinely  done  for  the  diagnosis  of  TB  in children. 
BACTERIOLOGY 
                     Demonstration of AFB from any body fluid or tissue is the 
gold standard of diagnosis of tuberculosis. Such a proof is often lacking in 
childhood tuberculosis  because of difficulty in collection  of sputum and 
due to paucibacillary primary disease in children. However, studies do 
report that the yield of  a  positive  test in  advanced cases may be as high 
as in adults. Few studies  have  reported as high as 33% bacteriological 
positivity even in primary disease  such  as  hilar  adenopathy.
(13,14)
 
Therefore, every attempt must be made to bacteriologically prove the 
diagnosis in every case of suspected tuberculosis. 
                     Early  morning gastric aspirate is a preferred specimen for 
most young  children with suspected  TB  for detecting AFB or isolating 
M. tuberculosis. The child is kept fasting for about 6 hours (at night) and 
an appropriate  size  intra-gastric tube is passed  in the morning. Initially 
the aspirate is drawn from the stomach and then a further washing with 15-
30 Ml saline is taken.The  contents so recovered are then immediately 
transferred to the laboratory. This  specimen  can  also  be  collected as an 
ambulatory procedure after  4-6 hours fasting
(15)
. Sputum collection is 
possible in older children with  extensive  and  cavitatory  disease, 
particularly  if the patient has a wet cough. Induction  of  sputum by 3% 
nebulized hypertonic saline can be tried in older  children (after the age of 
4 months). The  patient is pretreated with  nebulized  bronchodilators  prior  
to  induction. Following saline nebulisation, chest physiotherapy is done to 
loosen up the secretion and the samples are collected  from  the  throat  or  
nasopharynx.
(16)
 Whatever  method  one chooses to use, one needs to  
collect at least two, preferably three, samples. Where the facilities are 
limited, these tests may be prioritized and atleast be done in all children  
with wet cough or children who have definite parenchymal lesion on chest 
skiagram. 
                  Experience  with  bronchoscopy  and  bronchoalveolar  lavage 
(BAL) as a diagnostic tool is limited but it is often needed when evaluating 
persistent pneumonia. TB remains an important cause of persistent 
pneumonia in our country. Ziehl-Neelsen stain can reveal AFB only if 
sample contains >10,000 bacilli per mL. Different culture methods are 
used, such as LJ medium, Radiometric (Bactec) and Non-radiometric 
(MGIT)  can be used for confirming diagnosis in paucibacillary  state. The  
newer  methods  are capable of  giving faster  results  and  may  be used if 
available. Mycobacterial culture assumes special significance in  case of 
suspected drug resistance. 
MANTOUX 
                     The  standard tuberculin test recommended for use is  the    
Mantoux‘s test. Commercially available tuberculin  in the country are 1, 2 
and 5 Tuberculi  Unit  (TU) PPD (RT23 equivalent). It is important to raise  
a wheal of about  6 mm  after  the intra-dermal  injection  and  the test is 
read 48-72 hours after  an  injection. Ballpoint  or  palpatory methods are 
used to  read the induration. The  width of  reaction (induration) in  the  
horizontal  plane is noted for  interpretation .Mantoux‘s test or PPD skin 
test is considered positive if  the induration is 10 mm or more. This cut off 
was recommended using a 1 TU  PPD RT23. Currently  the  laboratories  
more  often  use 5 TU  PPD (RT23 equivalent), or sometimes even some  
other higher strengths or types of PPD are used. The  standard  cut off  of  
10 mm  can actually not be  justified for any higher strength of  PPD used. 
The  reaction evoked is not only dependent on the amount  of antigen 
given but also does not have a linear  relationship with the increasing 
strengths. Therefore, the  current  practice  may  actually lead to an 
increase  in false  positive  reactions  using  the 10mm cut off  with  the 
higher strength of PPD. The   Group  recommends  that  the 10mm  cut off  
may  be continued   to use  for  strengths  of  PPD  only  up to  5TU. 
Efforts  should  be  made to use only 1 TU PPD  to  decrease  the  false 
positives
(17)
 and  in  no  case strength  higher than  5 TU should  be  used. 
Degree of reaction, including  necrosis and ulceration, may  not  
necessarily differentiate  infected  from  diseased. Prior BCG  vaccine has 
minimal influence on PPD reaction
(18,19)
.  If the patient returns for reading 
beyond  72 hours  but by 7th day, a positive test can still be read. A  repeat 
test may be needed, if there is no induration  and the suspect presents 
beyond the stipulated time  for reading. Repeat tuberculin test when 
required should  preferably be done on the other arm. The  reading of the 
same should be interpreted as in any  other individual. 
CHEST  RADIOGRAPH 
               Chest  radiograph  merely localizes the site of  pathology and not 
etiology. There are no  pathognomonic radiological signs of tuberculosis. 
In  relevant clinical setting, certain radiological lesions  may strongly 
suggest tuberculosis  and  they include  miliary, hilar or paratracheal 
lymphadenopathy with  or without  parenchymal involvement and 
fibrocaceous  cavitatory lesions. Rarely chest X-ray may  be normal, such 
cases should be referred to an  appropriate center for further detailed 
investigations  if the clinical suspicion is high. In clinical practice, non-
resolving chest shadows  despite  adequate  antibiotic therapy in a 
symptomatic child raises the  possibility  of  tuberculosis. It is  worth  
mentioning  that all persistent radiological  lesions are  not necessarily due 
to TB.Asymptomatic patients may have persistent shadows due to 
parenchymal  scarring, pleural  thickening, and healed fibroatelectatic   
changes. On  the  other  hand, a  child with  bronchiectasis  or an interstitial 
lung disease may  have presence of non-resolving shadows with persistent 
symptoms.  Ultrasonography of chest is helpful to assess  pleural fluid 
collection; although decubitus chest X–  ray film may also reveal similar  
information. CT  scan is rarely  necessary  and  is  not cost and radiation  
effective. Chest CT scan, however,may offer an  opportunity  for CT 
guided biopsy  for tissue diagnosis. 
                          HUMAN  IMMUNODEFICIENCY  VIRUS 
AGENT   FACTOR 
                    HIV,the causative organism of AIDS is a member of the  
genus  Lentivirus,  part of the family of  Retroviridae.Lentiviruses have 
many  morphologies and   biological  properties  in common. Many species 
are infected by  lentiviruses, which  are  characteristically responsible for 
long-duration illnesses  with  a long  incubation  period. Lentiviruses  are 
transmitted as single-stranded, positive-sense, enveloped  RNA viruses. 
Upon  entry into the target  cell, the  viral  RNA  genome  is converted 
(reverse transcribed) into double-stranded  DNA  by a virally encoded  
reverse transcriptase  that is transported along with the viral genome in the 
virus particle. The resulting viral DNA  is  then  imported  into  the  cell 
nucleus and integrated into the cellular DNA  by  a virally encoded  
integrase  and  host co-factors.(20) Once integrated, the virus  may  become 
 latent, allowing  the virus and its host cell to avoid  detection by  the  
immune system. Alternatively, the virus may be transcribed, producing 
new  RNA genomes  and viral  proteins that are packaged and released 
from the cell as new virus particles that begin the replication cycle anew. 
                  Two  types  of  HIV have been characterized: HIV-1 and HIV-
2. HIV-1 is  the  virus  that  was  initially  discovered  and  termed  both  
LAV  and     HTLV-III. It  is  more  virulent, more  infective,(21) and  is  the 
cause of the majority  of  HIV infections  globally. The  lower  infectivity 
of HIV-2 compared to HIV-1 implies that fewer of those exposed to HIV-2 
will be infected per exposure. Because  of  its relatively poor capacity for 
transmission, HIV-2 is largely confined to West Africa.
  
STRUCTURE  AND  GENOME 
                    HIV is different in structure from other retroviruses. It is 
roughly spherical with  a  diameter  of  about 120 nm, around  60 times 
smaller than a  red blood cell, yet large for a virus. It is composed of two 
copies of positive single-stranded RNA that codes for the virus's nine  
genes enclosed by a conical  capsid  composed  of  2,000 copies  of the 
viral protein p24.
(22)
 The single-stranded  RNA  is  tightly  bound to 
nucleocapsid proteins, p7, and enzymes needed for the development of the 
virion such as  reverse transcriptase, proteases, ribonuclease  and integrase. 
A matrix composed of the viral protein p17 surrounds the capsid ensuring 
the integrity of the virion particle.(22) This  is, in  turn, surrounded  by  the  
viral  envelope  that is composed of  two layers of  fatty  molecules  called  
phospholipids  taken  from the membrane  of  a  human cell when a newly 
formed virus particle  buds from the cell. Embedded  in  the  viral  
envelope  are proteins from the host cell and about 70 copies  of  a 
complex HIV protein that protrudes through the surface of the virus 
particle.
[81]
 This protein, known as Env, consists of a cap made of three 
molecules called  glycoprotein (gp) 120, and a stem consisting of three  
gp41  molecules  that  anchor  the  structure  into  the  viral envelope. This 
glycoprotein complex enables the virus to attach to and fuse with target 
cells to initiate  the  infectious  cycle. Both these surface proteins, 
especially gp120, have  been  considered  as  targets  of  future treatments 
or vaccines against HIV.  
                    The RNA genome consists of at least seven structural 
landmarks (LTR, TAR, RRE, PE, SLIP, CRS, and INS), and nine genes 
(gag, pol, and  env, tat, rev, nef, vif, vpr, vpu, and sometimes a tenth tev, 
which is a fusion of tat env and rev), encoding 19 proteins. Three of these 
genes, gag, pol, andenv, contain information  needed  to  make  the  
structural proteins for new virus particles.(22) For  example,  env codes for a 
protein called  gp160 that is broken down by a viral enzyme to form gp120 
and gp41.The six remaining genes, tat, rev, nef, vif, vpr, and vpu (or vpx in 
the case of HIV-2), are regulatory genes for proteins that control the ability 
of HIV to infect cells, produce new copies  of  virus (replicate), or cause 
disease.(22)  
                    The two Tat proteins (p16 and p14) are transcriptional 
transactivators  for the LTR  promoter  acting by binding the TAR RNA 
element. The TAR may also be processed into  micro RNAs  that regulate 
the  apoptosis  genes  ERCC1  and  IER3. The  Rev protein (p19) is 
involved  in  shuttling  RNAs from the nucleus  and  the cytoplasm  by  
binding  to the  RRE RNA element. The Vif protein (p23)  prevents  the  
action of APOBEC3G (a cell protein that deaminates DNA:RNA  hybrids  
and/or interferes  with  the Pol protein). The Vpr protein (p14) arrests cell 
division at G2/M. The Nef protein (p27) down-regulates CD4 (the major 
viral receptor), as well as the MHC class I and class II molecules.  
                    Nef also interacts with SH3 domains. The Vpu protein (p16) 
influences the release of new virus particles from infected cells.
(22)
 The 
ends of each strand of HIV RNA contain an RNA sequence called the long 
terminal repeat (LTR). Regions in the LTR act as switches to control 
production of new viruses  and  can  be  triggered  by proteins from either 
HIV or the host cell. The  Psi  element is involved in viral genome 
packaging and recognized by Gag and Rev proteins. The SLIP element 
(TTTTTT) is involved in the frameshift in the Gag-Pol reading frame 
required to make functional Pol.(22)
  
 
TROPISM 
                     The  term  viral tropism refers to which cell types HIV 
infects. HIV can infect a variety of immune cells such as CD4
+
 T 
cells, macrophages, andmicroglial cells. HIV-1 entry to macrophages and 
CD4
+
 T cells is mediated through  interaction of  the virion envelope 
glycoproteins (gp120) with the CD4 molecule on the target cells and also 
with chemokine coreceptors.  
                    Macrophage (M-tropic) strains of HIV-1, or non-syncitia-
inducing strains (NSI) use  the  β-chemokine  receptor  CCR5 for  entry 
and are, thus, able to  replicate  in  macrophages and CD4
+
 T cells.
(23)
 This 
CCR5 coreceptor is used by  almost  all  primary  HIV-1  isolates  
regardless of viral genetic subtype. Indeed, macrophages play a key role in 
several critical aspects of HIV infection. They  appear  to be the first cells 
infected by HIV and perhaps the source of HIV production when 
CD4
+
 cells become depleted in the patient. Macrophages and microglial 
cells are the cells infected by HIV in  the  central nervous system. In 
tonsils and  adenoids of HIV-infected patients, macrophages fuse into 
multinucleated giant cells that produce huge amounts of virus. 
                    T-tropic isolates, or syncitia-inducing (SI) strains replicate in 
primary CD4
+
 T cells as well as in macrophages and use the α-chemokine 
receptor, CXCR4, for entry.(23) Dual-tropic HIV-1 strains are thought to be 
transitional strains of HIV-1 and thus are able to use both CCR5 and 
CXCR4 as co-receptors for viral entry. 
                    The α-chemokine SDF-1, a ligand for CXCR4, suppresses 
replication of T-tropic HIV-1 isolates. It does this by down-regulating the 
expression of CXCR4 on the surface of these cells. HIV that use only the 
CCR5 receptor are termed R5; those  that use only CXCR4 are termed X4, 
and those that use both, X4R5. However, the  use  of  coreceptor  alone 
does not explain viral tropism, as not all R5 viruses are able to use CCR5 
on macrophages for a productive infection(23) and HIV can also infect a 
subtype of myeloid dendritic cells,(24) which probably  constitute  a 
reservoir that maintains infection when CD4
+
 T cell numbers have declined 
to extremely low levels. 
                    Some people are resistant to certain strains of HIV. For 
example, people  with  the CCR5-Δ32  mutation are resistant to infection 
with R5 virus, as the mutation stops HIV from binding to this coreceptor, 
reducing its ability to infect target cells. 
TRANSMISSION  OF  HIV  IN CHILDREN 
                      In  children,  the  mode  of transmission is predominantly 
mother   to  child  (vertical transmission)  with  transmission rate varying 
from 25% to 40%.  The transmission   can  occur  intrauterine (materno-
fetal transfusion, placental inflammation),  intrapartum (on exposure to 
body fluids and cervical secretions at the time of labour) and through 
breast-feeding.  Infact  transmission through breast-feeding has been 
reported to vary from 14% to 29% in various studies. Thus, the ideal way 
to prevent vertical  transmission  of  HIV  would be to avoid  intrauterine,  
intrapartum and postpartum (breast-feeding) transmission of HIV.  
 
                     Transmission   of   HIV  by  transfusion  of  blood  and   
blood products   is  seen   in  patients    with   Thalessemia  and  patients  
with    Hemophilia or leukemia who require repeated transfusions.  
                Sexual  transmission  of  HIV  is  rare     and   is   seen   in   
patients   who have been sexually abused by HIV infected adults.  
                Transmission of HIV is found to be more during high viremia, 
recent  infection, low  CD4 count state and advanced stage of disease  and 
thus regular monitoring  for progression of the disease is essential. 
PATHOGENESIS 
                HIV virus when it enters into a susceptible host zooms to the 
lymphocytes (predominantly CD4 T cells) and infects the cells. After 
initial infection, there is a state of high replication leading to acute viral 
like illness. But the body‘s immune system subsequently recognizes the 
virus as foreign and builds an immune response by a complex interplay of 
various cytokines and proteins and leads to a latent phase whereby a 
balance is struck between the acute replication and immune response. This 
is a phase when the infected individual would be asymptomatic and just a 
laboratory investigation would reveal the infectivity status.  
 
        During the latent phase, the HIV virus lives predominantly in the 
lymphoid tissue and multiplies. Peripheral viremia is less. The person may 
just present with generalized lymphadenopathy. Once the fine balance 
between viral replication and immune response is overcome, the virus 
leads to peripheral blood over-pooling and viremia with destruction of 
CD4 T cells and immunosuppression. CD4 T cells also called as helper 
cells are the cells that lead to activation of CD8 T cells for cell mediated 
immunity and also help in conversion of B cells to plasma cells and 
generation of humoral immunity. With destruction of CD4 cells, both cell-
mediated immunity and humoral immunity is affected and a person 
becomes susceptible to opportunistic infections including viral, fungal, 
bacterial and parasitic and also has increased susceptibility to 
malignancies.  
 
        With increased destruction of CD4 T cells, the HIV virus replicates 
extensively and can also confer damage to the various organs of the body 
directly. Thus, a patient may have in addition various organ dysfunctions 
such as encephalopathy, nephropathy, cardiomyopathy, pulmonary disease, 
gastrointestinal disease, hepatitis and suppression of bone marrow.  
 
        In children, the latent phase is usually not seen, as there are several 
differences as compared to adults.  
1.  Children usually acquire the infection vertically whereas 
predominant mode of transmission    in adults is sexual. 
 2.  Children have an immature immune system at the time of 
acquisition of the virus. Thus,     with initial exposure to the virus, 
children have a prolonged viremia phase, the immune     system is 
not able to mount an adequate immune response and thus 
progression to AIDS is     faster.  
DIAGNOSIS  OF  HIV IN CHILDREN                    
                    As  maternal   HIV  antibody  transferred  passively during  
pregnancy  can  persist  for  as  long  as  18  months  in  children  born  to  
HIV-infected  mothers,  the  interpretation  of  positive  HIV  antibody  test  
results  is  more  difficult  in  children  below  this  age. Also, children  
who  are  breastfed have  ongoing  risk  for  HIV  acquisition:  therefore  
HIV  infection  can  only  be  excluded  after  breast-feeding  is  stopped  
for  > 6 weeks. In India, antibody  tests  and  ELISA  can  be  used  for  
infants  > 18 months as  per  adults; and  for  infants  < 18 months, DNA 
PCR  will  be  done  using  dried  blood  spots (DBS). 
 
              In  any  child  > 18  months  of  age, demonstration  of  IgG  
antibody  to HIV  by  a  repeatedly  reactive  enzyme  immunoassay (EIA)  
and  confirmatory  test (immunoblot  or  immunofluoresence  assay)  
establishes  the  diagnosis  of  HIV  infection. Incorporation  rapid  HIV 
testing  during  delivery  or  immediately  after  birth  is  crucial  for  the  
care  of  HIV-exposed  newborns  whose  HIV  status  was  unknown  
during  pregnancy. 
                  Following  diagnostic   tests  are  considerably   more  useful  in 
young  infants, allowing  a  definitive   diagnosis  in  most  infected   
infants  by  1 – 6  months  of  age.   
 
 
 
 
 
 TEST COMMENT 
HIV  DNA  PCR Preferred test to diagnose HIV-1 subtype B infection 
in infants and children younger than 18months of  age: 
highly sensitive and specific by 2wk of age and  
available; performed on peripheral blood mononuclear 
cells. False negatives can occur in non- B subtype 
HIV-1 infections.  
  HIV p24Ag Less sensitive; false positive results during 1 mo of 
life, variable results; not recommended. 
   ICD p24 Ag Negative test result does not rule out infection; not 
recommended. 
    HIV culture Expensive , not easily available, requires upto  4 wk to 
do test ; not  recommended 
HIV  RNA   PCR Not recommended for routine testing of  infants and  
children younger than 18 months of age, because a 
negative result cannot be used to exclude  HIV 
infection definitely. Preferred  test  to identify  non-B 
subtype  HIV-1 infections. 
             There  are  two  widely  used  classification  of  HIV/ AIDS   in  
children. 
1) WHO  clinical  staging  of  HIV /AIDS  for  children  with  
confirmed  HIV  infection. 
2) WHO  immunological  classification 
WHO Clinical Staging of HIV/AIDS and Case Definition  
                  The clinical staging and case definition of  HIV for resource-
constrained settings  were developed by the WHO in 1990 and revised in 
2006. Staging is based  on  clinical  findings  that guide the diagnosis, 
evaluation, and management of  HIV/AIDS,  and does not require a CD4 
cell count.  
                   This  staging  system  is  used in many countries to determine 
eligibility  for  antiretroviral  therapy. Clinical stages are categorized as 1 
through 4, progressing  from  primary HIV infection to  advanced 
HIV/AIDS. These stages are  defined by specific clinical conditions or 
symptoms. For the purpose of the WHO staging system, adolescents  and  
adults  are  defined as individuals aged ≥15 years.  
 
CLINICAL  STAGE  1 
      Asymptomatic 
      Persistent  generalized  lymphadenopathy 
CLINICAL  STAGE  2 
      Unexplained  persistent  hepatosplenomegaly 
      Papular  pruritic  eruptions 
      Extensive  wart  virus  infection 
      Extensive  molluscum  contagiosum 
      Fungal  nail  infections 
      Recurrent  oral  ulcerations 
      Unexplained  persistent  parotid  enlargement 
     Lineal  gingival  erythema 
      Herpes  Zoster 
     Recurrent  or  chronic  upper  respiratory  infections ( otitis media, 
otorrhoea, sinusitis  or  tonsillitis) 
CLINICAL  STAGE  3 
       Unexplained  moderate  malnutrition  not  adequately  responding  to 
standard  therapy 
      Unexplained  persistent  diarrhea ( 14 days  or  more)  
      Unexplained  persistent  fever (above  37.5° C intermittent  or  
constant,  for  longer  than  one  month) 
      Persistent  oral  candidiasis ( after  first  6 – 8 weeks  of  life) 
       Oral  hairy  leukoplakia 
     Acute  necrotizing  ulcerative  gingivitis  or  periodontitis 
      Lymph  node  tuberculosis 
      Pulmonary  tuberculosis 
     Severe  recurrent  bacterial  pneumonia 
     Symptomatic lymphoid  interstitial  pnemonitis 
     Chronic  HIV- associated  lung  disease  including   bronchiectasis 
     Unexplained  anaemia ( < 8 g /dl ), neutropenia ( < 0.5 × 10 9  per  liter ) 
and/ or  chronic  thrombocytopenia ( < 50 × 10 9 per  liter ) 
 
CLINICAL  STAGE 4b 
      Unexplained  severe  wasting, stunting or severe malnutrition not 
responding to standard therapy 
      Pneumocystis pneumonia 
      Recurrent severe bacterial infections(such as empyema, pyomyositis, 
bone or joint infection or meningitis but excluding pneumonia) 
      Chronic herpes simplex infection(orolabial or cutaneous of more than 
one month‘s duration or visceral at any site) 
      Extrapulmonary tuberculosis 
      Kaposi sarcoma 
      Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs) 
      Central nervous system toxoplasmosis (after one month of life) 
     HIV encephalopathy 
     Cytomegalovirus infection 
      Extrapulmonary cryptococcosis (including meningitis) 
     Disseminated endemic mycosis (extrapulmonary histoplasmosis, 
coccidiomycosis) 
     Chronic cryptosporidiosis 
     Chronic isosporiasis 
     Disseminated non-tuberculous mycobacterial infection 
      Cerebral or B-cell non-Hodgkin lymphoma 
      Progressive multifocal leukoencephalopathy 
      Symptomatic HIV-associated nephropathy or HIV-associated 
cardiomyopathy 
a. – Unexplained refers to where the condition is not explained by 
other causes. 
b. -  Some additional specific conditions can also be included in 
regional classifications (such as reactivation of American 
trypanosomiasis [ meningoencephalitis  and/or  myocarditis ]  in 
the  WHO Region of the Americas, penicilliosis  in  Asia and HIV-
associated rectovaginal fistula  in Africa). 
WHO  IMMUNOLOGICAL  CLASSIFICATION 
           Following   is   the  revised   classification  of  immune  suppression  
in  children 
HIV-associated  
 
immunodeficiency 
    <11        
 months 
(% CD4+) 
 12  -  35 
 months 
(% CD4+) 
  36 – 59 
 Months 
(% CD4+) 
 > 5 years 
cells/ cu.mm 
Not  significant       > 35     > 30    >  25    >  500 
Mild     30 - 35  25 - 30  20 – 25 350 – 499 
Advanced     25 - 30  20 – 25  15 – 20 200 – 349 
Severe   < 25 % or 
<1500cells/ 
    cu.mm 
   < 20 or  
<750cells/ 
    cu.mm 
   < 15 or  
<350cells/ 
    cu.mm 
< 15 % or  
<200cells/ 
    cu.mm 
                
In  children,  the  mode  of transmission is predominantly mother   to  
child  (vertical transmission). Risk  factors  for  perinatal transmission  and  
strategies  to  prevent  vertical   transmission  have  been  laid  down  by  
the  NACO.   
RISK  FACTORS FOR PERINATAL HIV TRANSMISSION
(25) 
                The  following   factors  are  associated  with  increased   risk  of  
vertical  transmission. 
i)Viral factors: High viral load, non-syncytium inducing phenotype, 
HIV-1 
ii)Maternal factors: Advanced disease (low CD4 count, symptoms of 
AIDS), primary infection of mother during pregnancy, first of twins, 
rupture of membranes more than four hrs, maternal bleeding, mother   
not on  antiretroviral therapy, vaginal delivery, other sexually  
transmitted diseases, isolated HIV-1 infection 
iii)Fetoplacental factors: chorioamnionitis, placenta previa, 
prematurity  (increased peripartum transmission) 
iv)Infant factors: HLA  concordance  with  mother 
v)Postnatal factors: breast feeding, higher breast milk virus load, 
mastitis or maternal nipple lesions, maternal seroconversion during 
breastfeeding, infant having thrush at less than six month age (in 
breastfeeding infant) 
Prevention of perinatal HIV 
            In the absence of any intervention the risk of perinatal 
transmission is 15–30% in non-breastfeeding populations(25). 
            Breastfeeding by an infected mother increases the risk by 5–
20%  to a  total of 20–45% (26). 
      The risk of MTCT can  be reduced to under 2% by  interventions 
that include antiretroviral (ARV) prophylaxis given to women 
during  pregnancy and labour and to the infant in the first 6 weeks 
of  life, obstetrical  interventions including elective caesarean 
delivery (prior to the onset of labour and rupture of membranes), 
and complete avoidance of breastfeeding 
(27-29)
. 
 
  1) ARV regimens for treating pregnant women
(30) 
A)  For  HIV-infected  pregnant  women  in need of ART  for  their 
own health, ART  should  be  administered  irrespective  of  gestational  
age  and continue throughout pregnancy, delivery and thereafter 
(recommended for all  HIV-infected pregnant women with CD4 cell 
count <350 cells/mm3,irrespective of WHO clinical staging; and for 
WHO clinical stage 3 or 4,irrespective of CD4 cell count) 
B)   Recommended  regimen  for  pregnant  women  with  indication  
for ART is combination of zidovudine (AZT), lamivudine (3TC) and 
nevirapine (NVP)or efavirenz (EFV) in antepartum, intrapartum and 
postpartum period;EFV-based  regimens  should not  be newly-initiated 
during the first trimester of pregnancy. 
C) Recommended regimen for pregnant women who are not eligiblefor  
ART, but for preventing MTCT is to start ART as early  as 14 weeks  
gestation or as soon as possible when women present late in pregnancy,   
in  labour or at delivery. Two options for ART are available: 
i)Option A:  daily AZT in antepartum period, combination of 
   single  dose  of  NVP  at onset of labour and dose of  AZT and 
              3TC during  labour  followed  by combination of AZT and 3TC 
             for 7 days in  postpartum period. 
ii)Option B: consists of triple ARV drugs starting as early as 14 
               weeks of  gestation until one week after all exposure to breast  
               milk has ended (AZT + 3TC + LPV or AZT + 3TC + ABC or 
              AZT + 3TC + EFV); [ABC= abacavir]. 
D) Omission of  the Single dose-NVP and AZT+3TC intra and 
postpartum may be considered for women who receive at least four 
weeks of AZT before  delivery. 
E) If  a woman received a three-drug regimen during pregnancy, a 
      Continued  regimen of  triple  therapy is recommended for mother 
     through  the end of  the breastfeeding period. 
2)ARV regimens for infants born to HIV infected mothers 
(31) 
i)For  breastfeeding  infants:  daily NVP from birth  until 6 weeks of 
age or until one week after all exposure to breast milk has ended. The 
dose of nevirapine is 10 mg/ d for infants < 2.5 kg; 15 mg/ d for infants 
more than 2.5 kg 
ii)For non-breastfeeding infants: daily AZT or daily NVP from birth 
until 6 weeks of age. The  dose of zidovudine is 4 mg/ kg twice a day. 
3)Intrapartum interventions 
i) Avoid rupture of membranes unless medically indicated. 
ii)  Delivery by elective caesarean section at 38 weeks before onset of 
labour and rupture of membranes. 
iii) Avoid procedures increasing risk of exposure of child to maternal 
blood and secretions like use of scalp electrodes. 
4)Breast feeding 
             Breast-feeding is an important mode of transmission of HIV 
infection in  developing countries. The risk of HIV infection via breast-
feeding is  highest in the early months of breast-feeding
(32)
 . Exclusive 
breastfeeding  has been reported to carry a lower risk of HIV transmission 
than  mixed feeding. 
Factors that increase the likelihood of transmission include 
Detectable  levels of HIV in breast milk, the presence of mastitis and low 
maternal  CD4+ T cell count. 
  Mothers known to be HIV-infected should only give commercial 
infant  formula milk as a replacement feed when specific conditions are 
met  (referred to as AFASS – affordable, feasible, acceptable, sustainable 
and  safe in the 2006 WHO recommendations on HIV and Infant 
Feeding)
(33) 
        Mothers known to be HIV-infected may consider expressing and 
heattreating  breast milk as an interim feeding strategy in special 
circumstances such as: 
 a)Low birth weight or is otherwise ill in the neonatal period and 
unable to breastfeed 
     b)Mother is unwell and temporarily unable to breastfeed 
     c)Temporary breast health problem such as mastitis 
     d)To assist mothers to stop breastfeeding 
     e) If antiretroviral drugs are temporarily not available 
       Replacement feeding should be given by katori spoon; bottle feeds 
should be avoided. 
       If replacement feeding is not feasible, mothers known to be HIV-
infected (and whose infants are HIV uninfected or of unknown HIV status) 
should exclusively breastfeed their infants for the first 6 months of life,  
introducing appropriate complementary foods thereafter, and continue  
breastfeeding for the first 12 months of life. Breastfeeding should then  
stop once a nutritionally adequate and safe diet without breast milk can  be 
provided. 
       Breastfeeding should stop gradually in one month. 
IMPACT  OF  HIV  ON  TB 
           HIV has a pronounced effect on the development of TB disease. 
About a third of HIV infected individuals worldwide are co-infected with 
TB infection. In some countries in  sub-Saharan Africa, up to 70 percent of 
patients with smear-positive pulmonary TB are  HIV positive 
(34)
. HIV 
fuels the TB epidemic  in several ways. HIV promotes the progression. 
          To active TB  disease, both  in people  with recently acquired TB 
infection  and  with latent M.tuberculosis  infection. HIV is the most 
powerful risk factor for reactivation of latent tuberculosis infection to 
active disease. HIV infected persons are more susceptible to  becoming 
infected with TB when exposed to M. tuberculosis. The annual risk of 
developing  TB disease in a PLWHA who is co-infected with M. 
tuberculosis is 5 to 15 percent 
(35)
 HIV increases  the  rate  of recurrent TB 
disease, which may be due to either endogenous reactivation (true relapse) 
or exogenous re-infection
(36)
. Increase in tuberculosis cases amongst the 
PLWHA poses an increased risk of TB transmission to the general 
community. 
                   An HIV infected person co-infected with M. tuberculosis has a 
50 percent lifetime risk of developing TB disease, whereas an HIV non-
infected person infected with M. tuberculosis has only a 10 percent risk of 
developing TB
(37,38)
. This is especially  important in India, where it is 
estimated that 40 percent  of  the adult  population is infected with M. 
tuberculosis. It is estimated that 50-60 percent of the HIV-infected persons 
in India will develop TB disease  during  their life-time
(39) 
IMPACT  OF  TB  ON  HIV     
           The course of HIV infection is accelerated following the acquisition  
of TB infection. The development of TB is associated with increased HIV-
1 replication and increased viral loads due to increased systemic immune 
activation as well as altered local cytokine milieu at sites of M. 
tuberculosis infection. Mycobacteria enhance HIV replication in tissues by 
inducing nuclear factor kappa-β, the cellular factor that binds to the 
promoter region of HIV. Mononuclear cell activation is a  feature of active 
TB disease. Mononuclear cells that express HLA-DR are the most 
productive source of HIV replication. Dysregulation in β chemokines and 
their receptors has been described during TB; this may contribute to 
enhanced viral dissemination. Programmed cell death of T cells is 
increased at the time of diagnosis of pulmonary TB in HIV-infected 
patients and may be partly responsible for further loss of immune 
responses directed to HIV-1. TB provides a milieu of continuous cellular 
activation and changes in cytokine and chemokine circuits that are 
permissive of viral replication and expansion in situ. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
AIM  OF  THE  STUDY 
        To  screen  for  TB  coinfection  in  HIV  positive  children  
registered in  ART Centre , Madurai. 
 
 
 
 
 
 
 
 
MATERIALS  AND  METHODS 
PLACE  OF  THE  STUDY 
        This  study  was  conducted  at  ART  centre  and  institute  of  child 
health  and  research  centre, Madurai. 
DURATION  OF   THE  STUDY 
            One  year  ( September  2010  -  August  2011 ) 
INCLUSION  CRITERIA 
                Children, who  are  HIV  positive  in  the  age  group  of  18 
months  to  12 years  registered  in  the  ART  centre. 
EXCLUSION  CRITERIA 
                   Children  less  than  18 months  were  not  included,  as  the 
facility  for  making  diagnosis  of  HIV  by  PCR  was  not  available  at  
the  ART  centre, Madurai. 
               Children  who  are taking  ATT 
METHODOLOGY 
Informed  consent  was  obtained   from  the  parent/ guardian  for  
registering  the  required  data. 
A  special  proforma  was  designed  to  record  the  following  
information. 
-   Demographic  data 
-   Anthropometry 
-   Parental  and  sibling  status 
-   Immunisation  status   
-   Developmental  milestones 
-   Contact  history 
-   Clinical  staging 
-   Immunological  staging 
 
The  children  were  subjected  to  the  following  investigations  that  
include 
-  Complete  blood  count 
-   ESR 
-   CD4  count 
-   Chest  X-ray 
-   Gastric  juice  for  AFB 
1.   Ziel – Neelson 
2.   Fluorescent  microscopy 
 
-  Mantoux 
- Lymph  node  biopsy / FNAC ( if  needed ) 
- LFT 
- Other  investigations (If necessary) 
1. USG  abdomen 
2.  CT scan 
3. CSF  analysis 
All  the  children  were  subjected to chest x-ray and tuberculin skin  
testing  to  detect  tuberculosis. Sputum  smear microscopy for acid fast 
bacilli (AFB) was   performed   from  the  sputum  specimens  obtained  
from  children, who were  found  or  motivated  to  expectorate  
themselves.  In very young patients, gastric juice aspirates were examined  
for AFB.  
              The overall clinical features, radiological findings, enhanced 
tuberculin indurations (>5 mm to  1 TU of PPD  is considered positive) 
and sputum smear microscopic  study  were  taken into consideration for 
diagnosing primary and  pulmonary tuberculosis.     
              Clinical presentation,  fine  needle aspiration cytology (FNAC) of 
lymph nodes,  enhanced tuberculin indurations (>5 mm to 1 TU of  PPD), 
smear microscopy  for  AFB from all the aspirates  and CSF, ultra 
sonography of abdomen  and/or CT  scan brain, wherever  needed, helped 
in diagnosing  extra-pulmonary tuberculosis. 
 
Statistical Analysis 
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2010) 
developed by Centre for Disease Control, Atlanta.  
 Using this software range, frequencies, percentages, means, standard 
deviations, chi square and 
 
'p'  values were calculated by One way ANOVA 
and ‗t‘ test. Kruskul Wallis chi-square test was used to test the significance 
of difference between quantitative variables and Yate‘s chi square test for 
qualitative variables.  
A 'p' value less than 0.05 is taken to denote significant relationship. 
 
    
 
 
 
 
 
  
OBSERVATIONS AND RESULTS 
 
 
TABLE 1 
STATISTICS OF HIV-INFECTED CHILDREN AT ART CENTRE, 
MADURAI as on August, 2009. 
 
  CHIDREN       MALE       FEMALE       TOTAL 
Registered   at 
       centre 
        377        379        756       
 On  ART     
 
       139        136        275 
Currently  on  
ART  at Madurai  
centre  
 
        74          74        148 
 
 
 
 
 
 
 TABLE 2  
NEWLY DIAGNOSED CASES DURING THE STUDY PERIOD 
 
          MALE      FEMALE      TOTAL 
SEPTEMBER             0             3             3 
OCTOBER             1             1             2 
NOVEMBER             1             3             4 
DECEMBER             7             1             8 
JANUARY             4             3             7 
FEBRUARY             1                       1             2 
MARCH             5             2             7 
APRIL             0             1             1 
MAY             2             0             2 
JUNE             1             3             4 
JULY             2             1             3 
AUGUST             2             0             2 
        TOTAL           26           19           45 
 
          
 
  
 
Table – 3 
Sex Distribution 
Total  number  of  children  screened  during  the  study period  -   103 
                                     
Sex No.of cases 
          MALE                                   64                       
        FEMALE             39 
 
 Of the 103 children screened for TB coinfection, 64 were male 
children and 39 were female children.   Male : female ratio is 1.64 : 1 
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TABLE -4 
IMMUNOLOGICAL   STAGING 
 
           The  103  children  were  categorized  based  on WHO  
immunological  system. 
The  results  were  as  follows 
 
Immunological Staging No.of cases Percentage 
     None or not significant            52         50.48% 
                  Mild                   26         25.24% 
                Advanced                  19         18.44% 
                   Severe            06         05.82% 
 
 Most of the children(50.48%) in the study group belonged to 
immunological staging none or not significant 
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 TABLE - 5 
POSITIVE  CASES 
 
 Screened  positive  
        for  TB 
Negative  for  TB 
         Male             8          56 
        Female             5          34 
         Total           13          90 
 
                  
    No.  children  screened  positive  for  tuberculosis  -  13. 
Tuberculosis co-infection in  our  study  was  found  to be 12.6% 
(n=13).   
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 TABLE - 6 
 CONTACT  HISTORY 
       
Contact History Total No.of cases 
Screened 
Screened  positive  
for   tuberculosis 
% 
Children  with  contact 
history 
14 10 71.42 
Children  without  
contact   history 
89 3 3.37 
Total 103 13  
 
 
          Out of 13 children screened positive for tuberculosis, 10(76.92%) 
children had contact with an open case of TB.       
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TABLE  7 
MANTOUX 
 
       Mantoux  testing   was  performed  on  all  the  children  and  the  
results  were as  follows:    
 
OBSERVATION No.of cases 
0  mm 70 
< 5  mm 22 
5 – 9 mm 09 
> 10 mm 02 
    
 
Mantoux positivity was observed in 10.67%(n=11) of screened children. 
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TABLE - 8 
CHEST  RADIOGRAPHY 
     
CHEST RADIOGRAPHY FINDINGS No.of cases 
   HILAR  ADENOPATHY 33 
   PLEURAL  EFFUSION 01 
    LOCALISED  PULMONARY  INFILTRATES  13 
  DIFFUSE INFILTRATES 03 
  MIDDLE LOBE CONSOLIDATION AND 
COLLAPSE 
 
01 
   BRONCHOPNEUMONIA 21 
 
           Hilar adenopathy was the most common radiological finding, found 
in 32%( n=33) of screened  children. 
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TABLE - 9 
GASTRIC JUICE/ SPUTUM MICROSCOPY 
 
               POSITIVE                 03 
              NEGATIVE               100 
 
                 AFB  was  demonstrable  only  in  3 cases, out  of  103 children 
screened for. 
3100
GASTRIC JUICE/ SPUTUM MICROSCOPY
POSITIVE
NEGATIVE
 
 
 
 
 
 
 
 
 
 
 
  
 
TABLE - 10 
LYMPH  NODE – FNAC 
 
                   Of  the  103 children screened  for  TB, 9 (8.7%)  children  
presented  with  lymphadenopathy.  
FNAC   was done  and  the  results  were  as  follows: 
Caseous   Granuloma           2    22.2% 
Reactive   Lymphadenitis           5    55.55% 
Follicular   Hyperplasia           2    22.22% 
 
                 Reactive  lymphadenitis  ( 55.5% ; n =5) was  the  most  
common  finding; followed  by  caseous  granuloma  and  follicular  
hyperplasis in  22.22% ( n=2). 
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TABLE 11: ANALYSIS  OF  POSITIVE  CASES 
 
CASE 
No. 
Contact  
History 
Mantoux Chest X-ray Sputum/Gastric  
juice 
Microscopy 
Other  
investigations 
  01     +   13 mm          Hilar 
    adenopathy 
       Negative  
  02   Nil   8  mm       Normal         Negative    FNAC + ve  
  03    +    6 mm      Middle  lobe  
   consolidation 
       Positive  
  04   Nil  0 mm  Pleural  Effusion        Negative  
  05     +   9 mm           Hilar   
   adenopathy 
      Negative  
  06     +  10 mm          Hilar   
   adenopathy 
       Negative  
  07     +   8  mm      Normal       Negative  
  08     +  2  mm          Hilar   
   adenopathy 
      Negative FNAC  + ve 
  09     +     8 mm Patchy  opacity  
in  R upper lobe 
      Positive  
  10     +   7 mm           Hilar   
   adenopathy 
      Negative USG-Abd  &  
 Ascitic fluid  
   analysis 
  11    Nil   8 mm          Hilar   
   adenopathy 
      Negative  
  12     +  8  mm      Normal       Negative  
  13     +   6  mm        Hilar   
   adenopathy 
     Positive  
 
     
DISCUSSION 
SEX  DISTRIBUTION  IN NEWLY  DIAGNOSED  CASES                       
                          Of  the  new   HIV  positive  children,  57.7 %(n=26) and  
42.2%(n=19)  were male  and  female  respectively. This  was  similar to 
S.Rajasekaran et al.,
(40)
 study at  Tambaram  in  which  male &  female  
children constituted  56.9 and 43.1  percent  respectively . Male  children  
outnumber female  children  by  a  small number. 
 CONTACT  HISTORY 
        Of  the  13  children screened  positive  for  tuberculosis, 10 children  
( 76.92%) had  contact  with  an  open  case  of  TB and  it  was  
Statistically  significant( p  value <0.0001) 
        This  was  similar  to  Ira shah et al
(41)
  study in which  70.7%  had  
contact  with an adult suffering from TB 
       Young  children   living in  close  contact  with a source case of smear-
positive  pulmonary TB   are at particular risk for TB infection and disease. 
The risk of  infection is greatest if the contact is close and prolonged, such 
as that between an   infant or toddler and the mother or other caregivers in 
the household. 
 
INCIDENCE 
                  Tuberculosis co-infection in  our  study  was  found  to be 
12.6% (n=13).    
                   Rajasekaran et al.
(40)
 reported TB coinfection in 63.1 % 
(n=1115) of HIV infected  children.  This  may  be due  to  high  referral  
and  larger population  studied  and  this  study  was  done  before  
initiation  of  ART. 
                Following  is  the  incidence  of  TB  in HIV infected children in  
various  Indian  studies. 
  
 Daga et al 
(42)
  n=28 
Dhurat et al. 
   
(43)
  n=55 
Lodha et al.  
 
(44)
    n=27 
Merchant et al. 
 
(45)
     n=285 
Our study 
   n=103 
Incidence 8(28.5%) 27(49%) 13(48.1%) 84(29.4%) 13(12.6%) 
 
                   Andrew  Edmonds  et al.
(46)
  reported  that    the TB incidence 
rate in those receiving ART was 10.2 per 100 person-years [95% 
confidence interval (CI) 7.4–13.9] compared with 20.4 per 100 person-
years (95% CI 14.6–27.8) in those receiving only primary HIV care. TB 
incidence decreased with time on ART, from 18.9 per 100 person-years in 
the first 6 months to 5.3 per 100 person-years after 12 months of ART. 
 
 
MANTOUX 
             Induration  of  > 5  mm  was  considered  positive. So 11 children  
were considered  positive  and their  cathegorization  based  on  WHO  
immunological  staging  is  as  follows: 
Immunological Staging No.of cases Percentage 
None or not significant 0 0 
Mild 8 73% 
Advanced 3 27% 
Severe 0 0 
 
               Even  in  HIV  positive  children,  induration of > 10  mm  was  
observed  in  two cases. 
             The  following  is  the  number  of  tuberculin  positive  cases  in  
various  Indian  studies: 
 Daga et al 
(42)
  n=28 
Dhurat et al. 
   
(43)
  n=55 
Lodha et al.  
 
(44)
    n=27 
Merchant et al. 
 
(45)
     n=285 
Our study 
   n=103 
Tuberculin 
positivity 
04 0 _ _ 11 
 
               The Mantoux test remains useful in the diagnosis of TB in 
children and is frequently positive even in HIV-infected children. In a 
recent study of Malawian children with suspected PTB, 11 out of 31 
Mantoux-positive children were HIV-infected.
(47)
 In this study, although 
less sensitive, the Mantoux was positive in 14 HIV-positive patients, 
comprising almost one third of the total number of positives. 
             
 GASTRIC JUICE/ SPUTUM MICROSCOPY 
             Only  in  3 cases, AFB  was  demonstrable. The  yield  of gastric 
juice/ sputum  microscopic  studies  was  low  due  to paucibacillary  
nature of TB infection  in  HIV-infected  children. 
            Berggren  Palme  et al.,
(48)
 study  stated  Direct microscopy for 
acid-fast bacilli was positive for 15% (n=55). 
CHEST  RADIOGRAPHY 
               In  the majority of cases, children with pulmonary TB  have CXR 
changes suggestive of TB. The commonest picture is that of persistent 
opaciﬁcation in the  lung together with enlarged hilar or subcarinal lymph 
glands.    
            Of   the  cases confirmed by Mantoux and Microscopy,  hilar  
adenopathy  was  observed  in  53.8% ( n=7); pleural effusion in 7.6 %       
( n=1) ; local  infiltrates  in  7.6 % ( n=1) ; middle  lobe  consolidation   in 
7.6 % ( n=1). 
           Vicci du plessis et al.
(49)  
stated  that  normal  radiographs  were  
reported  in  54%  of  HIV-infected  children. Those  with  radiographic  
abnormalities  had  parenchymal  disease (34%) ; mediastinal  disease 
(22%) ; and  pleural disease(1%). Radiological  appearances  of  TB were  
seen  in 9%  of  patients  
           
LYMPH NODE  FNAC 
             Of  the  103  children  screened  for  TB, 9 (8.7%)  presented  with  
lymphadenopathy,  FNAC  proved  to  be  TB  in  only 2 cases. Reactive  
lymphadenitis  was  the most common FNAC  finding. 
                But Shobhana et al.
(50)
 study  showed reactive hyperplasia in  
55.5%(n=30),  and    evidence    of tuberculous lymphadenitis  and  NHL  
in41%( n =22) and 3.7%( n = 2)  respectively. 
                Lakshmi  et al.
(51)
documented 186 cases of tubercular infection 
out of 643 HIV reactive cases, of which 14%( n=26) had TB lymphadenitis 
proven by FNAC and ZN stain.     
 
 
 
 
 
 
 
 
 
 CONCLUSION 
 
• HIV associated TB is a major public health problem. Tuberculosis 
co-infection  in HIV infected children was  found  to be 12.6%  in 
our study. This may be due to the impact  of ART. ART has been 
shown to reduce  the incidence of TB in treated cohorts even in high 
TB prevalence countries. 
• Source  of  childhood  TB   is  usually  an  adult, who  is  in close  
contact  with  the  children.   
• Mantoux  is  positive  even  in  HIV- infected  children. So  mantoux 
is  an  important  diagnostic  tool  even  in  HIV-infected  children. 
• FNAC  proved  to  be  TB  in  only 2 cases . So Lymphnode – 
FNAC or biopsy  is mandatory  for  children presenting with 
lymphadenopathy before starting empirical ATT. 
• With  the conventional  sputum  positivity  and Tuberculin test  not  
providing  an adequate  diagnostic  help, familiarity  with  clinco 
radiological spectrum of TB and HIV coinfection will help  in early 
diagnosis. 
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PROFORMA 
S.No   :                                        Date  of  Interview  
: 
NAME  :       AGE    : 
SEX      : 
ANTHROPOMETRY 
        HEIGHT          - 
        WEIGHT         -   
        MAC                - 
        AGE  AT  THE  TIME  OF  DIAGNOSIS  - 
                                TEST :  ELISA / WESTERN  BLOT/ DNA-PCR 
        HIV  STATUS  OF  PARENTS - 
            i)Mother (Reactive/Non-Reactive) 
                         (Alive/Dead) 
                          (on ART/ not on ART) 
           ii)Father(Reactive/Non-Reactive) 
                         (Alive/Dead) 
                         (on ART/ not on ART) 
ANTENATAL  HISTORY : 
i) HIV diagnosed before , 
 during or after pregnancy 
ii) Total  No. hospital  visits 
iii) TT injection  
iv) IFA intake 
v) Anaemia/ PIH / DM /APH 
MATERNAL  DELIVERY  DATA : 
i) Mode  of  delivery 
a) Vaginal 
                                  b) Assisted 
                                   c) Caesarean 
 ii) Place  of  delivery  
                                    a) Home 
                                     b) Institution 
 iii) Nevirapine prophylaxis  
                                     a) Received 
                                     b) Not received 
                                     c) Status  not known 
  iv) Feeding  Practices 
                                    a) Breast feed  alone 
                                     b)Artificial  feeds 
                                     c)Combined  breast &  artificial feeds                                                                                                                                                                                                                        
IMMUNISATION  STATUS : 
 
DEVELOPMENTAL MILESTONES : 
 
 
CONTACT  HISTORY :                                       
WHETHER  ON  COTRIMOXAZOLE  PROPHYLASIS  OR  NOT 
 
  
GENERAL  EXAMINATION :   
  Pallor                          - 
  Jaundice                    - 
  Generalised  lymphadenopathy-  
  Clubbing                     - 
  Pedal  edema           - 
  Oral  examination  -  Candidiasia / Oral  hairy        
                                                                 Leukoplakia 
  Cutaneous  manifestations – herpes  zoster/ 
                               Papular  pruritic  eruptions / 
                               Diffuse  skin  dryness 
                               Warts, molluscum 
                               Angular  cheilits  and  parotitis                       
SYSTEMIC  EXAMINATION : 
 
 
CLINICAL  STAGING: 
 
 
IMMUNOLOGICAL  STAGING: 
 
 
  
 
INVESTIGATION : 
1. Complete  blood  count 
2. Chest  X- ray 
3. Gastric  juice  for  AFB 
i) Ziel-Neelson 
ii) Fluorescent  microscopy 
4.  Mantoux 
5.  LFT 
6.  Other  Investigations 
 
FOLLOW  UP  OF  PATIENTS  ON  ART: 
     1)New  opportunistic  infection – yes/no 
                     (If yes, specify)                                        
     2) IRIS – yes/no  (If yes, specify) 
     3) ART  related  toxicity-yes/no  (If yes, specify)  
     4)Treatment  failure – yes/no (If yes, specify)                              
     5)Other  common  childhood  infection 
 
 
 
 
Se
ri
al
  N
o
. 
 A
G
E(
yr
s)
 
   
   
SE
X
 
B
C
G
  S
C
A
R
 
C
O
N
TA
C
T 
H
IS
TO
R
Y 
M
A
N
TO
U
X
 
M
IC
R
O
SC
O
P
Y 
 F
O
R
 
A
FB
 
C
H
ES
T 
 X
-R
A
Y 
O
TH
ER
 
IN
V
ES
TI
G
A
TI
O
N
S 
1 4 
     
M  Absent 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy   
2 11 
      
M Absent 
             
NIL       0 mm         Negative Localized  Infiltrates   
3 8 
      
M Absent 
             
NIL       0 mm         Negative Hilar adenopathy   
4 5 
      
F Absent 
             
NIL       0 mm         Negative Localized  Infiltrates   
5 6 
      
M Present 
             
NIL       0 mm         Negative                Normal FNAC  – ve 
6 3      F Absent 
             
NIL       0 mm         Negative Diffuse Infilatrates   
7 11 
      
M Present 
             
NIL 
       3 
mm         Negative                Normal   
8 7 
      
M Absent 
               
+      13mm         Negative     Hilar  adenopathy   
9 3 
      
F Present 
             
NIL       2 mm         Negative 
 
Bronchopneumonia   
10 8 
      
M Absent 
             
NIL       3 mm         Negative 
     Hilar  
adenopathy   
11 5 
      
F Present 
             
NIL       0 mm         Negative 
 
Bronchopneumonia   
12 8 
      
M Absent 
               
+       0 mm         Negative Localized  Infiltrates   
13 5 
      
M Absent 
             
NIL 
      8  
mm         Negative                Normal FNAC  + ve 
14 7      F Absent 
             
NIL       4 mm         Negative Localized  Infiltrates   
15 3 
      
F Absent 
             
NIL       0 mm         Negative 
 
Bronchopneumonia   
16 5 
      
M Absent 
             
NIL       0 mm         Negative                Normal   
17 8 
      
M Present 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy   
18 11 
      
F Present 
             
NIL       0 mm         Negative Localized  Infiltrates   
19 10 
      
M Absent 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy   
20 4 
      
M Absent 
             
NIL       0 mm         Negative 
 
Bronchopneumonia   
21 8 
      
F Present 
             
NIL       0 mm         Negative                Normal   
22 8 
      
F Absent 
               
+ 
      6  
mm        Positive     Consolidation   
23 4 
      
F Absent 
             
NIL       0 mm         Negative 
 
Bronchopneumonia   
24 8 
      
M Absent 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy   
25 11 
      
F Absent 
             
NIL       0 mm         Negative Hilar adenopathy   
26 12 
       
M Absent 
             
NIL       0 mm         Negative Pleural  Effusion   
27 8 
      
M Present 
             
NIL       0 mm         Negative                Normal   
28 5      F Absent 
             
NIL       0 mm         Negative 
 
Bronchopneumonia   
29 7 
      
M Absent 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy   
30 8 
     
M Absent 
             
NIL       0 mm         Negative                Normal   
31 4 
      
M Absent 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy   
32 9 
      
M Present 
               
+       2 mm         Negative                Normal   
33 4      F Present 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy   
34 10 
      
M Absent 
             
NIL 
      4  
mm         Negative                Normal   
35 6 
      
F Absent 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy FNAC  – ve 
36 12 
      
M Absent 
             
NIL 
      0  
mm         Negative 
     Hilar  
adenopathy   
37 9 
      
F Absent 
             
NIL       0 mm         Negative Localized  Infiltrates   
38 3 
     
M  Present 
             
NIL      2 mm         Negative 
 
Bronchopneumonia   
39 8 
      
F Present 
             
NIL       0 mm         Negative                Normal   
40 3 
      
M Absent 
             
NIL       0 mm         Negative 
 
Bronchopneumonia   
41 4 
     
M  Absent 
             
NIL       0 mm         Negative 
 
Bronchopneumonia   
42 4 
      
F Absent 
               
+       9 mm         Negative 
     Hilar  
adenopathy   
43 5 
      
M Absent 
             
NIL       0 mm         Negative 
 
Bronchopneumonia   
44 3 
      
F Absent 
             
NIL       0 mm         Negative 
 
Bronchopneumonia   
45 5 
       
F Absent 
               
+ 
      10 
mm         Negative 
     Hilar  
adenopathy   
46 3   M Absent            NIL       0 mm         Negative Bronchopneumonia   
47 8 
     
M Absent 
             
NIL       3 mm         Negative                Normal FNAC  – ve 
48 5 
      
F Present 
               
+       0 mm         Negative                Normal   
49 9 
      
M Absent 
             
NIL       2 mm         Negative 
     Hilar  
adenopathy   
50 11 
      
M Present 
             
NIL       0 mm         Negative                Normal   
51 5 
      
M Absent 
             
NIL       3 mm         Negative                Normal   
52 8 
      
F Present 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy   
53 4 
      
F Absent 
             
NIL       0 mm         Negative 
 
Bronchopneumonia   
54 8 
      
M Present 
             
NIL 
       4 
mm         Negative                Normal   
55 3 
      
M Absent 
             
NIL       0 mm         Negative Diffuse Infilatrates   
56 4 
        
F Absent 
               
+       8 mm         Negative 
 
Bronchopneumonia   
57 4 
      
M Absent 
             
NIL       0 mm         Negative                Normal   
58 8 
      
F Present 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy   
59 5 
      
M Absent 
             
NIL       0 mm         Negative                Normal   
60 4 
      
M Present 
             
NIL       0 mm         Negative 
 
Bronchopneumonia   
61 8 
      
F Absent 
             
NIL       2 mm         Negative                Normal FNAC  – ve 
62 6 
      
M Absent 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy   
63 11 
       
F Present 
             
NIL       0 mm         Negative Localized  Infiltrates   
64 5 
      
M Absent 
               
+       2 mm         Negative 
     Hilar  
adenopathy FNAC  +ve 
65 4 
      
M Absent 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy   
66 7 
       
F Absent 
             
NIL       0 mm         Negative Localized  Infiltrates   
67 7 
      
M Present 
             
NIL       0 mm         Negative                Normal   
68 5 
     
M  Absent 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy   
69 9 
      
M Absent 
             
NIL       0 mm         Negative                Normal   
70 9 
      
M Present 
             
NIL      3 mm         Negative                Normal   
71 8    M Absent      +       8 mm        Positive Localized  Infiltrates   
72 4 
      
M Absent 
             
NIL       2 mm         Negative                Normal   
73 9 
      
F Present 
             
NIL       0 mm         Negative                Normal   
74 6 
      
M Absent 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy   
75 8 
      
F Absent 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy   
76 4 
      
M Absent 
               
+       3 mm         Negative 
 
Bronchopneumonia   
77 8 
      
M Present 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy   
78 9 
      
F Absent 
             
NIL       3 mm         Negative                Normal FNAC  – ve 
79 4 
      
M Absent 
             
NIL       0 mm         Negative 
 
Bronchopneumonia   
80 3 
      
M Present 
             
NIL       0 mm         Negative                Normal   
81 6 
      
M Absent 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy   
82 5 
      
F Absent 
             
NIL       2 mm         Negative Localized  Infiltrates   
83 6 
      
F Present 
             
NIL       0 mm         Negative                Normal   
84 11 
      
M Absent 
               
+ 
      7  
mm         Negative 
     Hilar  
adenopathy 
FNAC  – ve 
USG Abd & 
Ascitic fluid 
analysis 
Positive 
85 6 
      
F Present 
             
NIL       0 mm         Negative                Normal   
86 5 
      
M Absent 
             
NIL       0 mm         Negative Localized  Infiltrates   
87 4 
      
F Present 
             
NIL       3 mm         Negative                Normal   
88 3 
      
M Absent 
             
NIL       8 mm         Negative 
     Hilar  
adenopathy   
89 4 
     
M Absent 
             
NIL       0 mm         Negative 
 
Bronchopneumonia   
90 8 
      
M Present 
             
NIL 
       2 
mm         Negative 
     Hilar  
adenopathy   
91 9 
      
M Absent 
             
NIL       0 mm         Negative Localized  Infiltrates   
92 11 
       
F Absent 
             
NIL 
       3 
mm         Negative                Normal   
93 2 
      
M Absent 
             
NIL       0 mm         Negative Diffuse Infilatrates   
94 6 
      
M Absent 
               
+ 
      8  
mm         Negative                Normal FNAC  – ve 
95 5      F Present            NIL       2 mm         Negative Bronchopneumonia   
96 9 
      
M Absent 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy   
97 4 
      
M Absent 
               
+       6 mm        Positive 
     Hilar  
adenopathy   
98 11 
     
M Absent 
             
NIL       0 mm         Negative Localized  Infiltrates   
99 4 
      
F Absent 
             
NIL       0 mm         Negative                Normal   
100 8 
     
M Absent 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy   
101 4 
       
F Absent 
             
NIL       0 mm         Negative 
 
Bronchopneumonia   
102 3 
      
M Present 
             
NIL       0 mm         Negative 
     Hilar  
adenopathy   
103 4 
       
F Absent 
             
NIL       0 mm         Negative 
 
Bronchopneumonia   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
